Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 15

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 15
---
. | IsletRx is Kadimastem’s                                                                                                          
 treatment for diabetes. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, 
 intended to treat and potentially cure patients with Type 1 diabetes and possibly Type 2 insulin dependent diabetes.             |

Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is currently listed on the Tel Aviv Stock Exchange (TASE: KDST). Company Overview Kadimastem is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off-the-shelf cell-based products for the treatment of unmet medical needs. Kadimastem operates in the field of development of cell therapy, regenerative medicine, for the treatment of, among others, ALS, an incurable disease, for which Kadimastem received an orphan drug designation status from the FDA, as well as cell therapy in the field of regenerative medicine for the treatment of diabetes, a disease that affects hundreds of millions of people worldwide, and its product has the potential to provide a cure for the disease. Kadimastem intends to be a leading company in the field of regenerative medicine products for the treatment of neurodegenerative diseases and a cure for diabetes.

<div align='center'>7</div>

Kadimastem is developing revolutionary
regenerative therapies based on stem cells-derived therapeutic cells, moving away from the traditional curative therapies. The technology
has been developed as a platform enabling the manufacturing of islet-like endocrine cells and glia restricted progenitors thus having
potential applications for diabetes, and for neurodegenerative diseases such as ALS. The therapy is scalable and industrialized, to be
commercialized as a stable “off the shelf” product and reduce the cost of treatments. For this, Kadimastem uses pluripotent
cells (e.g. embryonic stem cells - hESCs) that have a unique ability to multiply infinitely without losing their “naivety”
and to be able to become any cell type. The cell therapy products manufactured under Good Manufacturing Practices, or GMP, guidelines
(similar to traditional therapeutics) in order to reach optimal clinical results. Kadimastem developed a new process to differentiate